Etrasimod Arginine Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Etrasimod Arginine Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
36
Registered trials
75
Result records
2
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Etrasimod Arginine can convert its Small molecule drug profile and S1PR1 x S1PR4 x S1PR5 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Etrasimod Arginine (query alias: Etrasimod Arginine) |
|---|---|
| Modality / target | Small molecule drug; S1PR1 x S1PR4 x S1PR5; EDG6 agonists, S1PR1 agonists, S1PR5 agonists |
| Highest global status | Approved |
| Originator | Arena Pharmaceuticals, Inc. |
| Active developers | Pfizer Inc., Everest Medicines Ltd., Pfizer Europe MA EEIG |
The MCP disease footprint includes Ulcerative colitis, active moderate, Ulcerative colitis, active severe, Colitis, Ulcerative. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07486921 | Phase 2 | Recruiting | 40 | Proportion of participants with at least 1 episode of acute pouchitis |
| NCT07470879 | Phase 2 | Recruiting | 24 | Number and percent of enrolled participants with clinical remission based on Modified Mayo Score (MMS) at Week 52 |
| NCT07459686 | Not Applicable | Recruiting | 553 | The incidence of serious infections (adverse events and adverse drug reactions) and safety specifications (adverse drug reactions) |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
The Efficacy and Safety of Etrasimod in Mildly to Moderately Active Ulcerative Colitis: Results From the Phase II GLADIATOR Trial
Phase 2; n=374; evaluation: Positive. Reported fields: clinical remission(52-week) = 18.3 % ; clinical remission(52-week) = 26.0 %
Efficacy and safety of etrasimod in Japanese patients with ulcerative colitis: results from a phase 2 dose-ranging study
Phase 2; n=not disclosed; evaluation: Positive. Reported fields: clinical remission = 26.3 % ; clinical remission = 6.7 % ; -
P0924 Long-term etrasimod efficacy in patients with Ulcerative Colitis stratified by prior biologic/JAKi experience: 2-year outcomes from ELEVATE UC OLE
Phase 2/3; n=390; evaluation: Positive. Reported fields: Clinical Response(104-week) = 87.1 %
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Etrasimod Arginine addresses Ulcerative colitis, active moderate, Ulcerative colitis, active severe, Colitis, Ulcerative. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 2 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2021-12-13 | Pfizer Completes Acquisition of Arena Pharmaceuticals | Phase 3 | US$6,700.0M stated total |
| 2017-12-05 | Arena Pharmaceuticals and Everest Medicines Enter into Development and Commercialization Partnership for Ralinepag and Etrasimod in China | Phase 2 | US$12.0M upfront; US$212.0M milestones |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
